Adrenal Insufficiency Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F

Description

The Global Adrenal Insufficiency Market is projected to expand from USD 412.09 Million in 2025 to USD 701.45 Million by 2031, achieving a compound annual growth rate (CAGR) of 9.27%. This market encompasses diagnostic tests and therapeutic agents developed for conditions where the adrenal glands fail to synthesize adequate steroid hormones. Market growth is primarily fueled by the increasing prevalence of secondary adrenal insufficiency associated with prolonged glucocorticoid treatment for chronic inflammatory disorders. Furthermore, heightened clinician awareness and refined screening protocols are boosting diagnosis rates, thereby enlarging the patient demographic in need of hormone replacement therapy.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 412.09 Million
Market Size 2031	USD 701.45 Million
CAGR 2026-2031	9.27%
Fastest Growing Segment	Oral
Largest Market	North America

Despite this growth, the market encounters substantial obstacles related to preventing acute, life-threatening complications. The risk of fatal adrenal crises resulting from delayed treatment acts as a significant impediment to optimal patient care and market confidence. Data from the European Society of Endocrinology indicates that in 2025, the incidence of overt adrenal crisis was 4.4 cases per 100 person-years. This statistic underscores the enduring challenge of managing the condition effectively and highlights the urgent requirement for superior emergency therapeutic interventions.

Market Driver

The advancement of Research and Development and the broadening of therapeutic product pipelines are fundamentally transforming the market, specifically through the introduction of non-glucocorticoid treatments for conditions such as Congenital Adrenal Hyperplasia. Pharmaceutical companies are actively pursuing corticotropin-releasing factor type 1 (CRF1) receptor antagonists to alleviate the severe side effects linked to chronic high-dose steroid regimens. This clinical progress is illustrated by Crinetics Pharmaceuticals; as reported by BioSpace in January 2026, Phase 2 trial findings revealed that 88% of patients utilizing the investigational drug atumelnant reached physiologic glucocorticoid dosage levels. These developments indicate a strong commercial future for the industry, further emphasized by the rapid adoption of recently approved treatments. For example, BioSpace noted in January 2026 that Neurocrine Biosciences' newly approved drug Crenessity generated $165.3 million in revenue during the first three quarters of 2025, demonstrating substantial demand for effective treatments.

Furthermore, technological breakthroughs in drug delivery systems are propelling market growth by meeting the crucial demand for precise, age-specific dosing. The launch of modified-release capsules and multiparticulate granules has markedly enhanced treatment adherence, especially among pediatric patients who have traditionally faced difficulties with fractionated adult tablets. These advancements in delivery methods are yielding strong financial results for manufacturers specializing in niche adrenal insufficiency products. In February 2025, Eton Pharmaceuticals reported record quarterly product revenue of $11.6 million for the fourth quarter of 2024, a surge largely credited to the commercial success of its pediatric-specific hydrocortisone granules. These innovations ensure the patient population obtains consistent hormone replacement, thereby enhancing disease management and lowering the risk of acute complications.

Market Challenge

The central obstacle inhibiting the Global Adrenal Insufficiency Market is the enduring struggle to prevent acute and life-threatening complications, specifically adrenal crises. This safety barrier substantially erodes market confidence, as the inability to assure patient stability discourages the broad implementation of standard therapeutic protocols. The intricacy involved in adjusting hormone dosages to avert fatal episodes triggered by sudden physiological stress establishes a high-risk scenario that limits the growth of the treated patient population. Consequently, clinicians frequently exhibit reluctance to aggressively treat borderline cases because of the serious liability and health consequences linked to potential treatment failure, which in turn slows market momentum.

This challenge is exacerbated by the sheer magnitude of the population that requires precise safety monitoring to avert such complications. The logistical strain of preventing emergencies across such a vast group constrains the effectiveness of existing care delivery models. According to the Endocrine Society, in 2024, at least 1% of the general population was using chronic glucocorticoid therapy, a demographic recognized as being at perpetual risk for adrenal suppression and related emergencies. This statistic demonstrates the extent of the difficulty; the market faces a struggle to maintain consistent safety standards across this extensive patient base, which directly hinders the scalability of treatment solutions.

Market Trends

The creation of pre-filled autoinjectors for emergency crisis rescue is dramatically reshaping the safety landscape by meeting the urgent requirement for rapid intervention during adrenal crises. Existing emergency protocols frequently depend on complicated vial-and-syringe reconstitution kits, which are susceptible to user error and delays during high-stress situations. The introduction of pre-filled or needle-free auto-injector devices simplifies this procedure into a single, intuitive step, guaranteeing immediate hydrocortisone administration and lowering the probability of fatal results. This innovation constitutes a significant commercial sector; according to a March 2025 press release from Crossject, their strategic collaboration to commercialize the Zeneo hydrocortisone autoinjector addresses a market opportunity estimated to surpass $200 million in the United States alone.

Additionally, the growth of pediatric-specific oral liquid formulations is effectively bridging the gap in precise dose titration that solid oral dosage forms cannot resolve. Although recent granule-based therapies have enhanced adherence, liquid solutions provide superior flexibility, enabling clinicians to infinitely modify hormone replacement dosages to align with a child's rapid growth velocity and changing body surface area. This transition toward highly titratable liquid options is fueling strong financial optimism within the industry. As noted by Eton Pharmaceuticals in their "Second Quarter 2025 Financial Results" in August 2025, the company projected an annual revenue run rate of $80 million for the third quarter, a forecast bolstered by the addition of Khindivi, the first FDA-approved oral liquid hydrocortisone, to their portfolio.

Key Market Players

Acrotech Biopharma, Inc.
Bausch Health, Canada Inc
AdvaCare International Limited
Weefsel Pharma
Cipla Inc.
Pfizer Inc
Wellona Pharma
Eugia US LLC
Sandoz Inc.
Prevego Healthcare & Research Pvt Ltd

Report Scope

In this report, the Global Adrenal Insufficiency Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Adrenal Insufficiency Market, By Type

Primary
Secondary
Tertiary

Adrenal Insufficiency Market, By Treatment

Glucocorticoid
Corticotropin
Others

Adrenal Insufficiency Market, By Route of Administration

Oral
Injectables
Others

Adrenal Insufficiency Market, By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Adrenal Insufficiency Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Adrenal Insufficiency Market.

Available Customizations:

Global Adrenal Insufficiency Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Adrenal Insufficiency Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Primary, Secondary, Tertiary)
- 5.2.2. By Treatment (Glucocorticoid, Corticotropin, Others)
- 5.2.3. By Route of Administration (Oral, Injectables, Others)
- 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.5. By Region
- 5.2.6. By Company (2025)
5.3. Market Map

6. North America Adrenal Insufficiency Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Treatment
- 6.2.3. By Route of Administration
- 6.2.4. By Distribution Channel
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Adrenal Insufficiency Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Treatment
    - 6.3.1.2.3. By Route of Administration
    - 6.3.1.2.4. By Distribution Channel
- 6.3.2. Canada Adrenal Insufficiency Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Treatment
    - 6.3.2.2.3. By Route of Administration
    - 6.3.2.2.4. By Distribution Channel
- 6.3.3. Mexico Adrenal Insufficiency Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Treatment
    - 6.3.3.2.3. By Route of Administration
    - 6.3.3.2.4. By Distribution Channel

7. Europe Adrenal Insufficiency Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Treatment
- 7.2.3. By Route of Administration
- 7.2.4. By Distribution Channel
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Adrenal Insufficiency Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Treatment
    - 7.3.1.2.3. By Route of Administration
    - 7.3.1.2.4. By Distribution Channel
- 7.3.2. France Adrenal Insufficiency Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Treatment
    - 7.3.2.2.3. By Route of Administration
    - 7.3.2.2.4. By Distribution Channel
- 7.3.3. United Kingdom Adrenal Insufficiency Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Treatment
    - 7.3.3.2.3. By Route of Administration
    - 7.3.3.2.4. By Distribution Channel
- 7.3.4. Italy Adrenal Insufficiency Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Treatment
    - 7.3.4.2.3. By Route of Administration
    - 7.3.4.2.4. By Distribution Channel
- 7.3.5. Spain Adrenal Insufficiency Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Treatment
    - 7.3.5.2.3. By Route of Administration
    - 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Adrenal Insufficiency Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Treatment
- 8.2.3. By Route of Administration
- 8.2.4. By Distribution Channel
- 8.2.5. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Adrenal Insufficiency Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Treatment
    - 8.3.1.2.3. By Route of Administration
    - 8.3.1.2.4. By Distribution Channel
- 8.3.2. India Adrenal Insufficiency Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Treatment
    - 8.3.2.2.3. By Route of Administration
    - 8.3.2.2.4. By Distribution Channel
- 8.3.3. Japan Adrenal Insufficiency Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Treatment
    - 8.3.3.2.3. By Route of Administration
    - 8.3.3.2.4. By Distribution Channel
- 8.3.4. South Korea Adrenal Insufficiency Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Treatment
    - 8.3.4.2.3. By Route of Administration
    - 8.3.4.2.4. By Distribution Channel
- 8.3.5. Australia Adrenal Insufficiency Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Treatment
    - 8.3.5.2.3. By Route of Administration
    - 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Adrenal Insufficiency Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Treatment
- 9.2.3. By Route of Administration
- 9.2.4. By Distribution Channel
- 9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Adrenal Insufficiency Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Treatment
    - 9.3.1.2.3. By Route of Administration
    - 9.3.1.2.4. By Distribution Channel
- 9.3.2. UAE Adrenal Insufficiency Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Treatment
    - 9.3.2.2.3. By Route of Administration
    - 9.3.2.2.4. By Distribution Channel
- 9.3.3. South Africa Adrenal Insufficiency Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Treatment
    - 9.3.3.2.3. By Route of Administration
    - 9.3.3.2.4. By Distribution Channel

10. South America Adrenal Insufficiency Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Treatment
- 10.2.3. By Route of Administration
- 10.2.4. By Distribution Channel
- 10.2.5. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Adrenal Insufficiency Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Treatment
    - 10.3.1.2.3. By Route of Administration
    - 10.3.1.2.4. By Distribution Channel
- 10.3.2. Colombia Adrenal Insufficiency Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Treatment
    - 10.3.2.2.3. By Route of Administration
    - 10.3.2.2.4. By Distribution Channel
- 10.3.3. Argentina Adrenal Insufficiency Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Treatment
    - 10.3.3.2.3. By Route of Administration
    - 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Adrenal Insufficiency Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Acrotech Biopharma, Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Bausch Health, Canada Inc
15.3. AdvaCare International Limited
15.4. Weefsel Pharma
15.5. Cipla Inc.
15.6. Pfizer Inc
15.7. Wellona Pharma
15.8. Eugia US LLC
15.9. Sandoz Inc.
15.10. Prevego Healthcare & Research Pvt Ltd